United States Pharmacopeia Expands Vulnerable Drug List Amid Supply Chain Concerns
The United States Pharmacopeia (USP) has updated its list of drugs vulnerable to supply chain disruptions, adding medications such as Tamiflu and Trulicity. This update follows an expanded risk assessment that now includes key starting materials (KSMs), which are essential for producing active pharmaceutical ingredients. The USP's analysis revealed that 48 of the 100 vulnerable drugs rely on KSMs sourced from a single country, highlighting potential supply chain risks. Notably, 41% of KSMs for U.S.-approved active pharmaceutical ingredients are sourced solely from China, while 16% come from India. The USP's findings indicate that despite stable finished product availability, these drugs have a single upstream point of failure, making them susceptible to supply disruptions. 
